Bristol Myers Squibb (CELG-RI) Other Operating Expenses (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Other Operating Expenses of $4.1 billion for Q2 2026, down 33.87% year-over-year from $6.2 billion in Q2 2025, and up 2.96% quarter-over-quarter from $4.0 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Other Operating Expenses (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Other Operating Expenses for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Operating Expenses fell 33.87% year-over-year to $4.1 billion; the TTM figure through Jun 2026 stood at $19.1 billion (down 17.81% YoY), while the FY2025 annual figure was $21.6 billion, down 41.66% from the prior year.
- Other Operating Expenses climbed to $4.1 billion in Q2 2026 per CELG-RI's latest filing, from $4.0 billion in the prior quarter.
- Across five years, Other Operating Expenses topped out at $18.3 billion in Q1 2024 and bottomed at $4.0 billion in Q1 2026.
- Historically, Other Operating Expenses has averaged $6.0 billion across 5 years, with a median of $5.2 billion in 2023.
- Annual changes were most pronounced in 2024 — Other Operating Expenses surged 308.54% — and 2025, when it slumped 76.04%.
- Bristol Myers Squibb's Other Operating Expenses stood at $4.8 billion in 2022, then rose by 10.08% to $5.3 billion in 2023, then jumped by 30.24% to $6.8 billion in 2024, then slipped by 8.41% to $6.3 billion in 2025, then slumped by 34.53% to $4.1 billion in 2026.
- Business Quant data shows CELG-RI's Other Operating Expenses at $4.1 billion in Q2 2026, $4.0 billion in Q1 2026, and $6.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.10 Bn |
| Mar 31, 2026 | 3.98 Bn |
| Dec 31, 2025 | 6.27 Bn |
| Sep 30, 2025 | 4.79 Bn |
| Jun 30, 2025 | 6.20 Bn |
| Mar 31, 2025 | 4.39 Bn |
| Dec 31, 2024 | 6.84 Bn |
| Sep 30, 2024 | 5.86 Bn |
| Jun 30, 2024 | 6.09 Bn |
| Mar 31, 2024 | 18.32 Bn |
| Dec 31, 2023 | 5.25 Bn |
| Sep 30, 2023 | 4.58 Bn |
| Jun 30, 2023 | 5.18 Bn |
| Mar 31, 2023 | 4.48 Bn |
| Dec 31, 2022 | 4.77 Bn |
| Sep 30, 2022 | 4.66 Bn |
| Jun 30, 2022 | 5.82 Bn |
| Mar 31, 2022 | 5.87 Bn |
| Dec 31, 2021 | 5.26 Bn |
| Sep 30, 2021 | 4.70 Bn |